Medical Policy
Proteomic Testing for Systemic Therapy in Non-Small-Cell Lung Cancer

Table of Contents
- Policy: Commercial
- Policy: Medicare
- Authorization Information
- Coding Information
- Description
- Policy History
- Information Pertaining to All Policies
- References

Policy Number: 709
BCBSA Reference Number: 2.04.125
NCD/LCD: Local Coverage Determination (LCD): Molecular Pathology Procedures (L35000)

Related Policies
- Cerebrospinal Fluid and Urinary Biomarkers of Alzheimer Disease, #581
- Proteomics-based Testing for the Evaluation of Ovarian Masses, #249

Policy
Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

The use of proteomic testing, including but not limited to the VeriStrat assay, is considered INVESTIGATIONAL for all uses in the management of non-small-cell lung cancer.

Medicare HMO Blue℠ and Medicare PPO Blue℠ Members

This is not a covered service.

Medical necessity criteria and coding guidance for Medicare Advantage members living in Massachusetts can be found through the link(s) below.

Local Coverage Determinations (LCDs) for National Government Services, Inc.

Local Coverage Determination (LCD): Molecular Pathology Procedures (L35000)

Note: To review the specific LCD, please remember to click “accept” on the CMS licensing agreement at the bottom of the CMS webpage.

For medical necessity criteria and coding guidance for Medicare Advantage members living outside of Massachusetts, please see the Centers for Medicare and Medicaid Services website at https://www.cms.gov for information regarding your specific jurisdiction.
Prior Authorization Information

Inpatient
- For services described in this policy, precertification/preauthorization IS REQUIRED for all products if the procedure is performed inpatient.

Outpatient
- For services described in this policy, see below for products where prior authorization might be required if the procedure is performed outpatient.

<table>
<thead>
<tr>
<th>Outpatient</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Commercial Managed Care (HMO and POS)</td>
<td>This is not a covered service.</td>
</tr>
<tr>
<td>Commercial PPO and Indemnity</td>
<td>This is not a covered service.</td>
</tr>
<tr>
<td>Medicare HMO Blue&lt;sup&gt;SM&lt;/sup&gt;</td>
<td>This is not a covered service.</td>
</tr>
<tr>
<td>Medicare PPO Blue&lt;sup&gt;SM&lt;/sup&gt;</td>
<td>This is not a covered service.</td>
</tr>
</tbody>
</table>

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The following CPT codes are considered investigational for Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity, Medicare HMO Blue and Medicare PPO Blue:

<table>
<thead>
<tr>
<th>CPT Codes</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>81538</td>
<td>Oncology (lung), mass spectrometric 8-protein signature, including amyloid A, utilizing serum, prognostic and predictive algorithm reported as good versus poor overall survival</td>
</tr>
</tbody>
</table>

Description

Non-Small Cell Lung Cancer
Lung cancer is the leading cause of cancer death in the U. S., with an estimated 228,150 new cases and 142,670 deaths due to the disease in 2019.<sup>1</sup> NSCLC accounts for approximately 85% of lung cancer cases and includes nonsquamous carcinoma (adenocarcinoma, large cell carcinoma, other cell types) and squamous cell carcinoma.

Diagnosis
The stage at which lung cancer is diagnosed has the greatest impact on prognosis.<sup>2</sup> Localized disease confined to the primary site has a 55.6% relative 5-year survival but accounts for only 16% of lung cancer cases at diagnosis. Mortality increases sharply with advancing stage. Metastatic lung cancer has a relative 5-year survival of 4.5%. Overall, advanced disease, defined as regional involvement and metastatic, accounts for approximately 80% of cases of lung cancer at diagnosis. These statistics are mirrored for the population of NSCLC, with 85% of cases presenting as advanced disease and up to 40% of patients with metastatic disease.

In addition to tumor stage, age, sex, and performance status are independent prognostic factors for survival particularly in early-stage disease. Wheatley-Price et al (2010) reported on a retrospective pooled analysis of 2349 advanced NSCLC patients from 5 randomized chemotherapy trials.<sup>3</sup> Women had a
higher response rate to platinum-based chemotherapy than men. Additionally, women with adenocarcinoma histology had greater overall survival than men. A small survival advantage exists for squamous cell carcinoma over non-bronchiolar nonsquamous histology.\textsuperscript{4}

The oncology clinical care and research community use standard measures of performance status: Eastern Cooperative Oncology Group scale and Karnofsky Performance Scale.

**Treatment**

Treatment approaches are multimodal and generally include surgery, radiotherapy, and chemotherapy (either alone or in combination with another treatment, depending on disease stage and tumor characteristics). Per the National Comprehensive Cancer Network (NCCN) guidelines, the clinical management pathway for stage I or II NSCLC is dependent on surgical findings and may involve resection, radiotherapy, chemotherapy, or chemoradiation. First-line chemotherapy regimens for neoadjuvant and adjuvant therapy utilize platinum-based agents (e.g., cisplatin, carboplatin) in combination with other chemotherapeutics and/or radiotherapy. Treatment recommendations are based on the overall health or performance status of the patient, presence or absence of metastases, as well as the presence or absence of a treatment-sensitizing genetic variant. These aspects inform the selection of targeted and systemic therapies.\textsuperscript{1}

For patients who experience disease progression following initial systemic therapy, subsequent treatment regimens are recommended, mainly featuring novel programmed death-ligand 1 (PD-L1) inhibitors. For patients with sensitizing epidermal growth factor receptor (EGFR) mutations, recommendations include first-line therapy with EGFR tyrosine kinase inhibitors (TKIs) afatinib, erlotinib, dacomitinib, gefitinib, or osimertinib and subsequent therapy with osimertinib. The NCCN does not make any recommendations for the use of EGFR TKIs in the absence of a confirmed sensitizing EGFR mutation. For patients with progression on TKIs other than osimertinib, testing for T790M is recommended, however, switching to osimertinib can be considered regardless of mutational status. Osimertinib carries a Category 1 recommendation for T790M+ patients with disease progression on an alternative EGFR TKI. For progression on osimertinib with limited and/or isolated lesions, a continuation of osimertinib and definitive local therapy via surgery, stereotactic ablative radiotherapy, or stereotactic radiosurgery is recommended. Initial systemic therapy recommendations can be considered for multiple, symptomatic, systemic lesions.\textsuperscript{1}

**Genomic Alterations**

Several common genetic alterations in NSCLC have been targets for drug therapy, the most well-established of which are TKIs targeting the EGFR and crizotinib targeting the anaplastic lymphoma kinase (ALK) gene rearrangement.

**EGFR Variants**

EGFR, a tyrosine kinase (TK) receptor, is frequently overexpressed and activated in NSCLC. Drugs that inhibit EGFR-signaling either prevent ligand-binding to the extracellular domain (monoclonal antibodies) or inhibit intracellular TK activity (small molecule TKIs). These targeted therapies dampen signal transduction through pathways downstream to the EGFR, such as the RAS/RAF/MAPK cascade. RAS proteins are G proteins that cycle between active and inactive forms in response to stimulation from cell surface receptors such as EGFR, acting as binary switches between cell surface EGFR and downstream signaling pathways. These pathways are important in cancer cell proliferation, invasion, metastasis, and the stimulation of neovascularization.

Variants in 2 regions of the \textit{EGFR} gene, including small deletions in exon 19 and a point mutation in exon 21 (L858R), appear to predict tumor response to TKIs such as erlotinib. The prevalence of \textit{EGFR} variants in NSCLC varies by population, with the highest prevalence in nonsmoking Asian women with adenocarcinoma; for that subpopulation, \textit{EGFR} variants have been reported to as high as 30% to 50%. The reported prevalence of \textit{EGFR} variants in lung adenocarcinoma patients in the U. S. is approximately 15%.\textsuperscript{5}
**ALK Variants**

For 2% to 7% of NSCLC patients in the U.S., tumors express a fusion gene comprising portions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the ALK gene (EML4-ALK), which is created by an inversion on chromosome 2p.\(^6\) The EML4 fusion leads to ligand-independent activation of ALK, which encodes a receptor TK whose precise cellular function is not completely understood. EML4-ALK variants are more common in never smokers or light smokers, tend to be associated with younger age of NSCLC onset, and typically do not occur in conjunction with EGFR variants.

Testing for the EML4-ALK fusion gene in patients with adenocarcinoma-type NSCLC is used to predict response to the small molecule TKI crizotinib.

**Other Genetic Variants**

Other genetic variants, identified in subsets of patients with NSCLC, are summarized in Table 1. The role of testing for these variants is to help select targeted therapies for NSCLC is less well-established than for EGFR variants.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Gene Function</th>
<th>Estimated Variants Prevalence in NSCLC</th>
<th>Patient and Tumor Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>KRAS</td>
<td>Encodes RAS proteins; variants associated with constitutively activated protein</td>
<td>20%-30%</td>
<td>Adenocarcinomas Heavy smokers</td>
</tr>
<tr>
<td>ALK</td>
<td>Encodes a receptor TK in the insulin receptor family</td>
<td>4-5%</td>
<td>Never smokers Male Advanced disease</td>
</tr>
<tr>
<td>ROS1</td>
<td>Encodes a receptor TK in the insulin receptor family</td>
<td>0.9%-3.7%</td>
<td>Adenocarcinoma Never smokers</td>
</tr>
<tr>
<td>RET</td>
<td>Proto-oncogene that encodes a receptor TK growth factor</td>
<td>0.6%-2%</td>
<td></td>
</tr>
<tr>
<td>MET</td>
<td>Oncogene that encodes a receptor TK that is activated in response to binding of hepatocyte growth factor</td>
<td>2-4% of previously untreated NSCLC; 5%-20% of patients with acquired resistance to EGFR TKIs</td>
<td>Patients with acquired resistance to EGFR TKIs</td>
</tr>
<tr>
<td>BRAF</td>
<td>Serine-threonine kinase downstream from RAS in RAS-RAF-ERK-MAPK pathway</td>
<td>1%-3% of adenocarcinomas</td>
<td>Heavy smokers</td>
</tr>
</tbody>
</table>
### Gene Function

<table>
<thead>
<tr>
<th>Gene</th>
<th>Estimated Variants</th>
<th>Prevalence in NSCLC</th>
<th>Patient and Tumor Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>HER</td>
<td>HER (EGFR) family of TK receptors; dimerizes with EGFR family members when activated</td>
<td>1%-2% of NSCLC</td>
<td>Adenocarcinomas Nonsmoking women</td>
</tr>
<tr>
<td>PIK3CA</td>
<td>Intracellular signaling pathway</td>
<td>»4% of NSCLC</td>
<td></td>
</tr>
</tbody>
</table>

ALK: anaplastic lymphoma kinase; EGFR: epidermal growth factor receptor; HER: human epidermal growth factor receptor; NSCLC: non-small-cell lung cancer; TK: tyrosine kinase; TKI: tyrosine kinase inhibitor.

### Targeted Treatment Options

#### EGFR-Selective Small Molecule TKIs

Five orally administered EGFR-selective small-molecule TKIs have been approved by the U.S. Food and Drug Administration (FDA) for treating NSCLC: gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib (see Table 2). Although the FDA approved gefitinib in 2004, a phase 3 trial has suggested gefitinib was not associated with a survival benefit. In 2003, the FDA revised gefitinib labeling, further limiting its use to patients who had previously benefited or were currently benefiting from the drug; no new patients were to be given gefitinib. However, in 2015, the FDA approved gefitinib as a first-line treatment for patients with metastatic, sensitizing EGFR variant positive NSCLC.

In 2015, osimertinib (Tagrisso), an irreversible selective EGFR inhibitor that targets T790M variant-positive NSCLC, received the FDA approval for patients with T790M variant-positive NSCLC who have progressed on an EGFR TKI.

A meta-analysis by Lee et al (2013) assessing 23 trials on the use of erlotinib, gefitinib, and afatinib in patients with advanced NSCLC reported improved progression-free survival (PFS) in EGFR variant-positive patients treated with EGFR TKIs in the first- and second-line settings and as maintenance therapy. Comparators were chemotherapy, chemotherapy and placebo, and placebo in the first-line, second-line, and maintenance therapy settings. Among EGFR variant-negative patients, PFS was improved with EGFR TKIs compared with placebo for maintenance therapy but not in the first- and second-line settings. OS did not differ between treatment groups in either variant-positive or variant-negative patients. Statistical heterogeneity was not reported for any outcomes. Reviewers concluded that EGFR-variant testing is indicated to guide treatment selection in NSCLC patients.

On the basis of the results of five, phase 3 randomized controlled trials, the American Society of Clinical Oncology has recommended that patients with NSCLC being considered for first-line therapy with an EGFR TKI (patients who have not previously received chemotherapy or an EGFR TKI) should have their tumor tested for EGFR variants to determine whether an EGFR TKI or chemotherapy is the appropriate first-line therapy.

The primary target population for TKIs in NSCLC is for EGFR variant-positive patients with advanced NSCLC. The use of TKIs in NSCLC for patients with non-sensitizing, wild-type EGFR-variant status is controversial. The TITAN trial as reported by Ciuleanu et al (2012) demonstrated no significant differences in OS between erlotinib and chemotherapy as a second-line treatment for patients unselected on the basis of EGFR-variant status, with fewer serious adverse events in erlotinib-treated patients. Karampeazis et al (2013) reported similar efficacy between erlotinib and standard...
chemotherapy (pemetrexed) for second-line therapy in patients unselected on the basis of EGFR-variant status. By contrast, in the TAILOR trial, as reported by Garassino et al (2013), standard chemotherapy was associated with longer OS than erlotinib for second-line therapy in patients with wild-type EGFR. Auliac et al (2014) compared sequential erlotinib plus docetaxel with docetaxel alone as second-line therapy among patients with advanced NSCLC and EGFR wild-type or unknown status. Based on Simon’s optimal 2-stage design, the erlotinib plus docetaxel strategy was rejected. Despite the rejection, it is worth noting that in the erlotinib plus docetaxel arm 18 of the 73 patients achieved PFS at 15 weeks; comparatively, in the docetaxel arm, 17 of 74 patients achieved PFS at 15 weeks.

Cicenas et al (2016) reported on results of the IUNO randomized controlled trial, which compared maintenance therapy using erlotinib followed by second-line chemotherapy if progression occurred with placebo followed by erlotinib if progression occurred in 643 patients who had advanced NSCLC and no known EGFR variant. Because there were no significant differences between groups in PFS, objective response rate, or disease control rate, maintenance therapy with erlotinib in patients without EGFR variants was not considered efficacious.

Exon 19 deletions and p.L858R point mutations in exon 21 are the most commonly described sensitizing EGFR mutations, or mutations in EGFR that are associated with responsiveness to EGFR TKI therapy. According to the NCCN, most recent data indicate that NSCLC tumors that do not harbor a sensitizing EGFR mutation should not be treated with an EGFR TKI in any line of therapy.

Anti-EGFR Monoclonal Antibodies
For the treatment of KRAS-mutated NSCLC, anti-EGFR monoclonal antibodies have been investigated as possible treatment options. Available anti-EGFR monoclonal antibodies include cetuximab and panitumumab. The NCCN states that a combination of afatinib and cetuximab may be considered in patients harboring sensitizing EGFR mutations with disease progression on EGFR TKI therapy.

Programmed Death-Ligand 1 Inhibitors
Some tumors, including some NSCLCs, express aPD-L1 on the cell surfaces to interact with host T cells and evade the immune system. Several humanized monoclonal antibodies have been developed to act as immune checkpoint inhibitors by interfering with this interaction, to interact with the PD-L1, block cancer/T-cell interaction, and thus act as immune checkpoint inhibitors. Pembrolizumab, nivolumab, and atezolizumab, which inhibit the programmed death 1 receptor, and atezolizumab, which inhibits the PD-L1, are used in NSCLC that have a PD-L1 expression on its cells. Durvalumab also targets the PD-L1 protein but is used in unresectable, stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiotherapy.

Other Targeted Therapies
Crizotinib is a novel MET, ROS1, and ALK TKI, and associated with improved PFS in patients with advanced NSCLC who test positive for ALK gene rearrangements. Crizotinib is considered first-line therapy for advanced ALK-positive lung adenocarcinoma. Other small-molecule TKIs, designed to selectively bind to and inhibit ALK activation, have the FDA approval: ceritinib, alectinib, and brigatinib. Proposed targeted therapies for other genetic alterations in NSCLC are trastuzumab for HER2 variants, crizotinib for MET amplification and ROS1 rearrangement, vemurafenib and dabrafenib for BRAF variants, and cabozantinib for RET rearrangements.

Proteomics Testing for Selecting Targeted Treatment for NSCLC
The term proteome refers to the entire complement of proteins produced by an organism, or cellular system and proteomics refers to the large-scale comprehensive study of a specific proteome. The proteome may differ from cell to cell and may vary over time and in response to selected stressors.
A cancer cell’s proteome is related to its genome and genomic alterations. The proteome may be measured by mass spectrometry (MS) or protein microarray. For cancer, proteomic signatures in the tumor or bodily fluids (ie, pleural fluid or blood) other than the tumor have been investigated as a biomarker for cancer activity.

A commercially available serum-based test (VeriStrat) has been developed and proposed to be used as a prognostic tool to predict expected survival for standard therapies used in the treatment of NSCLC. The test is also proposed to have predictive value for response to EGFR TKIs. The test uses matrix-assisted laser desorption ionization MS analysis, and a classification algorithm was developed on a training set of pretreatment sera from 3 cohorts (Italian A, Japan A, Japan B) totaling 139 patients with advanced NSCLC who were treated with second-line gefitinib. The classification result is either “good” or “poor”. Two validation studies using pretreatment sera from 2 cohorts of patients (Italian B, Eastern Cooperative Oncology Group 3503) totaling 163 patients have been reported (see Tables 3 and 4).

This assay uses an 8-peak proteomic signature; four of the eight have been identified as fragments of serum amyloid A protein 1. This protein has been found to be elevated in individuals with a variety of conditions associated with acute and chronic inflammation. The specificity for malignant biologic processes and conditions has not been determined. With industry support, Fidler et al (2018) used convenience biorepository samples to investigate 102 analytes for potential correlations between the specific peptide and protein biomarkers and VeriStrat classification. The VeriStrat test is currently marketed as a tool to measure a patient’s “immune response to lung cancer.” Biodesix indicates that a VeriStrat “Good” result indicates “a disease state that is more likely to respond to standard of care treatment,” whereas a VeriStrat “Poor” rating indicates a chronic inflammatory disease state associated with aggressive cancer and patients that “may benefit from an alternative treatment strategy.” The Biodesix website does not indicate whether the VeriStrat test should be reserved for use in patients with advanced lung cancer.

Although the VeriStrat matrix-assisted laser desorption ionization MS-based predictive algorithm has the largest body of literature associated with it, other investigators have used alternative MS methods, such as surface-enhanced laser desorption ionization/time-of-flight MS, and alternative predictive algorithms, to assess proteomic predictors of lung cancer risk.

Best practices for peptide measurement and guidelines for publication of peptide and protein identification have been published for the research community.

Table 2. Targeted Treatment Options Approved by FDA

<table>
<thead>
<tr>
<th>Drug</th>
<th>Indication</th>
<th>Manufacturer</th>
<th>Approved</th>
<th>NDA/BLA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gefitinib</td>
<td>Monotherapy for locally advanced or metastatic NSCLC after failure of platinum-based and docetaxel chemotherapies</td>
<td>AstraZeneca</td>
<td>05/03</td>
<td>NDA 21-399 (Discontinued)</td>
</tr>
<tr>
<td>(Iressa®)</td>
<td></td>
<td></td>
<td>06/05</td>
<td>NDA 206995</td>
</tr>
<tr>
<td></td>
<td>Revised label to limit use to patients currently benefiting or previously benefited from gefitinib</td>
<td></td>
<td>08/18</td>
<td>NDA 206995/S3</td>
</tr>
<tr>
<td></td>
<td>First-line treatment of patients with metastatic</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>Drug</th>
<th>Indication</th>
<th>Manufacturer</th>
<th>Approved</th>
<th>NDA/BLA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erlotinib (Tarceva®)</td>
<td>NSCLC whose tumors have <em>EGFR</em> exon 19 deletions or exon 21 (L858R) substitution variants as detected by an FDA-approved test</td>
<td>OSI Pharmaceuticals and Genentech</td>
<td>11/04 04/10 05/13 10/16</td>
<td>NDA 021743 NDA 021743/S16 NDA 021743/S18 NDA 021743/S25</td>
</tr>
<tr>
<td>Drug</td>
<td>Indication</td>
<td>Manufacturer</td>
<td>Approved</td>
<td>NDA/BLA</td>
</tr>
<tr>
<td>----------------</td>
<td>----------------------------------------------------------------------------</td>
<td>--------------</td>
<td>----------</td>
<td>----------------</td>
</tr>
<tr>
<td>Afatinib (Gilotrif®)</td>
<td>First-line treatment of patients with metastatic NSCLC whose tumors have <em>EGFR</em> exon 19 deletions or exon 21 (L858R) substitution variants as detected by an FDA-approved test. Treatment of patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy. Treatment of patients with NSCLC whose tumors have nonresistant <em>EGFR</em> variants as detected by an FDA-approved test, which includes variants other than <em>EGFR</em> exon 19 deletions or exon 21 (L858R) substitution variants.</td>
<td>Boehringer Ingelheim</td>
<td>07/13 04/16 01/18</td>
<td>NDA 201292 NDA 201292/S7 NDA 201292/S14</td>
</tr>
<tr>
<td>Necitumumab (Portrazza®)</td>
<td><em>EGFR</em> antagonist indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous NSCLC.</td>
<td>Eli Lilly</td>
<td>11/15</td>
<td>BLA 125547</td>
</tr>
<tr>
<td>Osimertinib (Tagrisso®)</td>
<td>Treatment of patients with metastatic <em>EGFR</em> T790M variant-positive NSCLC, as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy. First-line treatment of patients with metastatic NSCLC whose tumors have, as detected by an FDA-approved test, EGFR</td>
<td>AstraZeneca</td>
<td>11/15 08/18</td>
<td>NDA 208065 NDA 208065/S11</td>
</tr>
<tr>
<td>Drug</td>
<td>Indication</td>
<td>Manufacturer</td>
<td>Approved</td>
<td>NDA/BLA</td>
</tr>
<tr>
<td>--------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-------------------</td>
<td>------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>Crizotinib</td>
<td>Treatment of patients with locally advanced or metastatic NSCLC that is ALK-positive as detected by an FDA-approved test&lt;br&gt;Treatment of patients with metastatic NSCLC whose tumors are ROS1-positive&lt;br&gt;Treatment of patients with metastatic NSCLC whose tumors are ROS1- or ALK-positive</td>
<td>Novartis</td>
<td>08/11&lt;br&gt;03/16&lt;br&gt;06/19</td>
<td>NDA 202570&lt;br&gt;NDA 202570/S16&lt;br&gt;NDA 202570/S28</td>
</tr>
<tr>
<td>Ceritinib</td>
<td>A kinase inhibitor indicated for treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib&lt;br&gt;A kinase inhibitor indicated for treatment of patients with ALK-positive metastatic NSCLC</td>
<td>Novartis</td>
<td>04/14&lt;br&gt;03/19</td>
<td>NDA 205755 (Discontinued)&lt;br&gt;NDA 211225</td>
</tr>
<tr>
<td>Alectinib</td>
<td>A kinase inhibitor indicated for treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib&lt;br&gt;A kinase inhibitor indicated for treatment of patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test</td>
<td>Hoffman-La Roche</td>
<td>12/15&lt;br&gt;06/18</td>
<td>NDA 208434&lt;br&gt;NDA 208434/S4</td>
</tr>
<tr>
<td>Drug</td>
<td>Indication</td>
<td>Manufacturer</td>
<td>Approved</td>
<td>NDA/BLA</td>
</tr>
<tr>
<td>------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>------------------------</td>
<td>----------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>Brigatinib (Alunbrig®)</td>
<td>Treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib</td>
<td>ARIAD</td>
<td>04/17</td>
<td>NDA 208772</td>
</tr>
</tbody>
</table>
| Pembrolizumab (Keytruda®)    | Treatment of patients with metastatic, PD-L1-positive NSCLC, as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy  
Treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥ 1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy  
Expansion of metastatic NSCLC indication to include first-line treatment of patients whose tumors have high PD-L1 expression (TPS ≥50%) as determined by an FDA-approved test, with no *EGFR* or *ALK* genomic tumor aberrations  
Use in combination with pemetrexed and carboplatin, for the first-line treatment of patients with metastatic nonsquamous, NSCLC | Merck                  | 10/15 10/16 10/16 05/17 | BLA 125514/S5 BLA 125514/S8 BLA 125514/S12 BLA 125514/S16 |
<p>| Nivolumab (Opdivo®)          | Treatment of patients with metastatic NSCLC with progression on or after platinum-based chemotherapy. Patients with <em>EGFR</em> or <em>ALK</em> genomic                                                                 | Bristol-Myers Squibb  | 10/15    | BLA 125554/S005              |</p>
<table>
<thead>
<tr>
<th>Drug</th>
<th>Indication</th>
<th>Manufacturer</th>
<th>Approved</th>
<th>NDA/BLA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atezolizumab (Tecentriq®)</td>
<td>Metastatic NSCLC patients who have disease progression during or following platinum-containing chemotherapy. Patients with <em>EGFR</em> or <em>ALK</em> gene tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Tecentriq.</td>
<td>Genentech</td>
<td>4/17</td>
<td>BLA 761034</td>
</tr>
<tr>
<td>Durvalumab (Imfinzi®)</td>
<td>Treatment of patients with unresectable, stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiotherapy</td>
<td>AstraZeneca</td>
<td>02/18</td>
<td>BLA 761069/S-002</td>
</tr>
<tr>
<td>Dacomitinib (Vizimpro®)</td>
<td>First-line treatment of patients with metastatic NSCLC with <em>EGFR</em> exon 19 deletion or exon 21 L858R substitution variants, as detected by an FDA-approved test</td>
<td>Pfizer</td>
<td>09/18</td>
<td>NDA 211288</td>
</tr>
<tr>
<td>Larotrectinib (Vitrakvi®)</td>
<td>A kinase inhibitor indicated for the treatment of patients with solid tumors that have an <em>NTRK</em> gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe</td>
<td>Bayer</td>
<td>11/18</td>
<td>NDA 210861</td>
</tr>
<tr>
<td>Drug</td>
<td>Indication</td>
<td>Manufacturer</td>
<td>Approved</td>
<td>NDA/BLA</td>
</tr>
<tr>
<td>--------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>----------</td>
<td>---------------</td>
</tr>
<tr>
<td>Lorlatinib (Lorbrena®)</td>
<td>A kinase inhibitor indicated for the treatment of patients with ALK-positive metastatic NSCLC whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease, or alectinib as the first ALK inhibitor for metastatic disease, or ceritinib as the first ALK inhibitor for metastatic disease</td>
<td>Pfizer</td>
<td>11/18</td>
<td>NDA 210868</td>
</tr>
<tr>
<td>Dabrafenib (Tafinlar®)</td>
<td>A kinase inhibitor indicated for the treatment of patients with metastatic NSCLC with BRAF V600E mutation as detected by an FDA-approved test</td>
<td>Novartis</td>
<td>07/19</td>
<td>NDA 202806/S13</td>
</tr>
<tr>
<td>Trametinib (Mekinist®)</td>
<td>A kinase inhibitor indicated for the treatment of patients with metastatic NSCLC with BRAF V600E mutation as detected by an FDA-approved test</td>
<td>Novartis</td>
<td>07/19</td>
<td>NDA 204114/S13</td>
</tr>
<tr>
<td>Entrectinib (Rozlytrek®)</td>
<td>A kinase inhibitor for the treatment of patients with metastatic ROS1-positive NSCLC</td>
<td>Genentech</td>
<td>08/19</td>
<td>NDA 212726</td>
</tr>
</tbody>
</table>

**ALK**: anaplastic lymphoma kinase; **BLA**: biologics license application; **EGFR**: epidermal growth factor receptor; **FDA**: Food and Drug Administration; **NDA**: new drug application; **NSCLC**: non-small-cell lung cancer; **PD-L1**: programmed death-ligand 1; **TKI**: tyrosine kinase inhibitor; **TPS**: Tumor Proportion Score.
Summary
Proteomic testing has been proposed as a way to predict survival outcomes, as well as the response to and selection of targeted therapy for patients with non-small-cell lung cancer (NSCLC). One commercially available test (the VeriStrat assay) has been investigated as a predictive marker for response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.

For individuals with newly diagnosed NSCLC and wild-type EGFR-variant status who receive management with a serum proteomic test to predict survival and select treatment, the evidence includes retrospective studies and a prospective nonrandomized study. The relevant outcomes are overall survival (OS), disease-specific survival, and treatment-related mortality and morbidity. No published studies were identified that assessed the prognostic use of VeriStrat proteomic testing in newly diagnosed stage I or II NSCLC. For individuals with newly diagnosed advanced NSCLC and EGFR-negative variant status without prior systemic therapy, five studies have assessed the use of VeriStrat (“good” or “poor”) as a prognostic test to discriminate between OS (primary) and progression-free survival (PFS) (secondary) outcomes. All studies were retrospective and intended to validate the extent to which the VeriStrat proteomic classification correlated with OS or PFS. Only one of the five studies reported the percentage of participants who were EGFR-negative, but it did not report outcomes based on variant status. One observational, nonrandomized study with prospective sample collection for proteomic testing before NSCLC treatment reported the percentage of participants who were EGFR-negative, but it did not report outcomes based on variant status. This was also the only study that included a first-line treatment consistent with current guideline-based recommendations - platinum-double-based chemotherapy plus cisplatin or carboplatin plus pemetrexed. The VeriStrat classification was not used to direct the selection of treatment in any of the clinical trials from which the validation samples were derived. Disposition of populations with variant status “not reported” was generally not clear and could not be construed as “unknown” when wild-type or positive were reported. No studies were identified that used VeriStrat proteomic testing to inform therapeutic options for patients with stage I or II NSCLC if surgery or surgery plus radiotherapy have been completed or who were upstaged as a result of surgical findings. No studies were identified that used VeriStrat proteomic testing to inform therapeutic options for patients with stage I or II NSCLC who were considered medically inoperable. No studies were identified that used VeriStrat proteomic testing to predict response to first-line targeted therapies or first-line chemotherapy in patients with newly diagnosed advanced NSCLC. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with newly diagnosed NSCLC and unknown EGFR-variant status who receive management with a serum proteomic test to predict survival and select treatment, the evidence includes a randomized controlled trial (RCT), four retrospective studies, and a prospective study. The relevant outcomes are OS, disease-specific survival, and treatment-related mortality and morbidity. All study populations were either unselected for EGFR-variant status or status was expressly reported as unknown in conjunction with negative or positive status reports. None of the studies that reported unknown EGFR-variant status reported outcomes for the proteomic score based on unknown EGFR-variant status. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with NSCLC and wild-type EGFR-variant status and disease progression after first-line systemic therapy who receive management with a serum proteomic test to predict survival and select treatment, the evidence includes a RCT and a retrospective analysis. The relevant outcomes are OS, disease-specific survival, and treatment-related mortality and morbidity. No studies were identified that reported or analyzed outcomes using the proteomic test as a prognostic tool in EGFR-negative variant status populations. The evidence includes an RCT (PROSE) using proteomic testing to predict response to erlotinib compared with chemotherapy as a second-line treatment for patients with stage IIIB or IV NSCLC, stratified by performance status, smoking history, treatment center, and (masked) pretreatment VeriStrat classification. In a multivariate model to predict OS, which included clinical characteristics and EGFR-variant status, VeriStrat classification was significantly associated with OS (hazard ratio for VeriStrat “good” vs “poor,” 1.88; 95% confidence interval, 1.25 to 2.84; p=0.003). However, 62% of the combined study population was EGFR-negative. A retrospective analysis was also performed on the
MARQUEE trial, a phase 3 RCT in patients with stage IIIIB or IV nonsquamous NSCLC, comparing the patient response to erlotinib in conjunction with either tivantinib or a placebo; patients were stratified by EGFR and KRAS variant status, sex, smoking history, and treatment history. Protocol treatments were subsequently discontinued by 93% of patients, and the trial discontinued after prespecified interim futility analysis. In a multivariate model to predict OS, which included clinical characteristics and EGFR-variant status, VeriStrat classification was significantly associated with OS (hazard ratio for VeriStrat “good” vs “poor,” 0.52; 95% confidence interval, 0.40 to 0.67; p<0.001). Ninety percent of the combined study population was EGFR-negative. An interaction between treatment and VeriStrat status was significant for multivariate analysis including EGFR status (p=0.036) but not significant for multivariate analysis including both EGFR and KRAS variant status (p=0.068). Currently, the use of erlotinib in patients unselected for the presence or absence of an EGFR-sensitizing variant is not standard clinical practice. It is recommended that variant status be determined, if not previously ascertained, before selecting treatment after progression or recurrence. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with NSCLC and unknown EGFR-variant status with disease progression after first-line systemic therapy who receive management with a serum proteomic test to predict survival and select treatment, the evidence includes two RCTs and three retrospective studies. The relevant outcomes are OS, disease-specific survival, and treatment-related mortality and morbidity. The use of VeriStrat as a prognostic test to discriminate between good and poor survival outcomes was assessed in three retrospective studies intended to validate the extent to which VeriStrat proteomic classification correlates with OS or PFS. The VeriStrat classification was not used to direct treatment selection in any of the trials from which the validation samples were derived. None of the clinical trials from which the samples for VeriStrat proteomic classification were derived used a therapy consistent with current guidelines-based recommendations. The populations in all three studies were unselected for EGFR-variant status. In the PROSE RCT, using a multivariate model to predict OS, which included clinical characteristics and EGFR-variant status, VeriStrat classification was significantly associated with OS (hazard ratio for VeriStrat “good” vs “poor,” 1.88; 95% confidence interval, 1.25 to 2.84; p=0.003). However, 32.6% of the combined study population had unknown EGFR status. In the EMPHASIS RCT, there were no significant differences in PFS or OS among patients with VeriStrat “good” status receiving erlotinib or chemotherapy or among patients with VeriStrat “poor” status receiving erlotinib or chemotherapy. The results of the EMPHASIS RCT were restricted to squamous NSCLC histology. Currently, the use of erlotinib in patients unselected for the presence or absence of an EGFR-sensitizing variant is not standard clinical practice. It is recommended that variant status be determined, if not previously ascertained, before selecting treatment after progression or recurrence. The evidence is insufficient to determine the effects of the technology on health outcomes.

### Policy History

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>09/2018</td>
<td>BCBSA National medical policy review. Description, summary and references updated. Policy statement unchanged. 9/1/2018</td>
</tr>
<tr>
<td>8/2017</td>
<td>BCBSA National medical policy review. In the Background, in the discussion of osimertinib, NSCLC variant T890M changed to T790M. 8/1/2017.</td>
</tr>
<tr>
<td>5/2017</td>
<td>BCBSA National medical policy review. Background section clarified programmed death ligand 1 inhibitors are not only used for cancers expressing PD-L1. 5/1/2017</td>
</tr>
</tbody>
</table>
New references added from BCBSA National medical policy.

Non-coverage for Medicare Advantage members clarified based on Local Coverage Determination (LCD): Molecular Pathology Procedures (L35000). 2/2017

Clarified coding information.

Policy updated to include Medicare LCD L35396. Effective 12/1/2015.


Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

- Medical Policy Terms of Use
- Managed Care Guidelines
- Indemnity/PPO Guidelines
- Clinical Exception Process
- Medical Technology Assessment Guidelines

References


30. Stinchcombe TE, Roder J, Peterman AH, et al. A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the

